Ascendiant Capital Maintains Buy on Surgepays, Lowers Price Target to $5

Benzinga Newsdesk www.benzinga.com Negative 85.6%

Neg 85.6% Neu 0% Pos 0%

Ascendiant Capital analyst Edward Woo maintains Surgepays (NASDAQ:SURG) with a Buy and lowers the price target from $9.75 to $5.